TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Primary Purpose
Urinary Bladder Neoplasms
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cryoablation
Epirubicin
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Bladder Neoplasms focused on measuring Bladder Cancer, Cryoablation
Eligibility Criteria
Inclusion Criteria:
- Clinically diagnosed bladder tumor, stage T1 or T2
- Number of lesions ≤ 3
- Tumor size ≤ 3cm
Exclusion Criteria:
- With other malignant diseases
- T3 or above
- Enlarged pelvic lymph node or distant metastasis
- Poor overall condition
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
TUR with Cryoablation
TUR with instant instillation
Arm Description
Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
Outcomes
Primary Outcome Measures
Residual tumor rate
The investigators would perform reTUR 4-6 weeks after initial surgery to detect residual tumor
Secondary Outcome Measures
Indwelling time
Adverse event rate
Full Information
NCT ID
NCT02760953
First Posted
April 22, 2016
Last Updated
October 17, 2017
Sponsor
Huashan Hospital
Collaborators
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Zhejiang Provincial People's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02760953
Brief Title
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Official Title
A Multi Center, Randomized, Parallel Controlled Study of Applying Transurethral Resection of Bladder Tumor With Adjuvant Cryoablation to Treat Bladder Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 19, 2017 (Anticipated)
Primary Completion Date
October 30, 2018 (Anticipated)
Study Completion Date
December 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Huashan Hospital
Collaborators
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Zhejiang Provincial People's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of applying cryoablation as an adjuvant therapy with TUR to treat bladder tumor.
Detailed Description
Bladder tumors are one of the most commonly diagnosed urinary tumors in the world. Worldwide, it has been estimated that 429,800 new cases of and 165,100 deaths due to bladder tumor occurred in 2012. Transurethral resection (TUR) is the gold-standard treatment for non-muscle invasive bladder cancer (NMIBC). In muscle-invasive bladder cancer, TUR also plays a vital role as a bladder-sparing procedure regardless of whether it is applied as a monotherapy or in combination with chemo-radiotherapy.
Whether radical resection of a tumor is initially performed can be essential in the treatment of bladder tumors. Incomplete TUR influences a patient's prognosis, regardless of whether it is part of a NMIBC treatment or part of bladder-sparing trimodal therapy. However, the quality of TUR is one of the greatest concerns in the treatment of bladder tumor. After initial TUR, approximately 70% of patients exhibit incomplete resection re-staging TUR. Of these patients, 30% exhibit residual tumors at the resection site. To solve this problem, a second TUR 4-6 weeks after the initial TUR is recommended by the guidelines, and these repeated TURs detect residual tumors in 26-83% of cases.
The investigators sought to identify other therapies that can be combined with TUR to eliminate residual tumors. As a minimally invasive method, cryotherapy has been widely used for urological tumors, including prostate tumor and kidney tumor. With respect to bladder tumors, cryotherapy remains in the exploration phase. Only a few studies of the use of computed tomography (CT)-guided percutaneous cryoablation for the treatment of bladder cancer have been reported. Unlike solid viscera, such as the prostate or kidney, the bladder exhibits the features of hollow viscera. Cryoablation through the transurethral approach could be possible if the safety of the procedure can be ensured. Our recent animal study conducted in a porcine model demonstrated the feasibility and safety of transurethral focal, full-thickness cryoablation. No perforations were observed during two eight-minute freeze cycles. Based on the success of transurethral cryoablation in animal experiments, the investigators performed this study to explore the safety and efficacy of cryoablation as an adjuvant therapy with TUR in the treatment of bladder tumors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Bladder Neoplasms
Keywords
Bladder Cancer, Cryoablation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TUR with Cryoablation
Arm Type
Experimental
Arm Description
Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
Arm Title
TUR with instant instillation
Arm Type
Active Comparator
Arm Description
Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
Intervention Type
Procedure
Intervention Name(s)
Cryoablation
Intervention Description
Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
Intervention Type
Drug
Intervention Name(s)
Epirubicin
Intervention Description
Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
Primary Outcome Measure Information:
Title
Residual tumor rate
Description
The investigators would perform reTUR 4-6 weeks after initial surgery to detect residual tumor
Time Frame
4-6 weeks after surgery
Secondary Outcome Measure Information:
Title
Indwelling time
Time Frame
One month after surgery
Title
Adverse event rate
Time Frame
Through study completion, an average of 2 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinically diagnosed bladder tumor, stage T1 or T2
Number of lesions ≤ 3
Tumor size ≤ 3cm
Exclusion Criteria:
With other malignant diseases
T3 or above
Enlarged pelvic lymph node or distant metastasis
Poor overall condition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shenghua Liu, Doctor
Phone
+86 021 52889999
Email
liushenghuafy@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Haowen Jiang, Doctor
Organizational Affiliation
Huashan Hospital
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
26939677
Citation
Liu S, Zou L, Mao S, Zhang L, Xu H, Yang T, Jiang H, Ding Q. The safety and efficacy of bladder cryoablation in a beagle model by using a novel balloon cryoprobe. Cryobiology. 2016 Apr;72(2):157-60. doi: 10.1016/j.cryobiol.2016.02.007. Epub 2016 Mar 3.
Results Reference
background
PubMed Identifier
17826526
Citation
Hruby GW, Marruffo F, Ortiz J, Durak E, Edelstein A, Levi G, Landman J. Transurethral bladder cryoablation in the porcine model. Urology. 2007 Aug;70(2):391-5. doi: 10.1016/j.urology.2007.03.028.
Results Reference
background
Learn more about this trial
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
We'll reach out to this number within 24 hrs